American Century Investments Focused Dynamic Growth Fund stated in its Q2 2026 investor letter that it had sold its holdings in biotechnology company Regeneron Pharmaceuticals (NASDAQ:REGN). The fund noted that it was disappointed with the slow commercialization progress of Regeneron's macular degeneration treatment and believed its stock had limited appreciation potential, thus choosing to reallocate capital to other more attractive investments.